Skye Bioscience, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Punit S. Dhillon
- Full Time Employees
- 16
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 11250 El Camino Real San Diego CA United States of America 92130
- IPO Date
- Nov 26, 2014
- CIK
- 0001516551
- Website
- skyebioscience.com
- Similar Companies
- Business
- Skye Bioscience, Inc. Skye Bioscience, Inc. (Nasdaq: SKYE) is a clinical-stage biotechnology company that develops next-generation molecules modulating G-protein coupled receptors, primarily targeting the cannabinoid receptor 1 (CB1) for the treatment of obesity, overweight, and metabolic diseases with significant unmet needs. The company offers nimacimab, a peripherally restricted negative allosteric modulating antibody that inhibits CB1 to promote weight loss and improve metabolic conditions, including as monotherapy or in combination with GLP-1 receptor agonists such as semaglutide (Wegovy®) or tirzepatide; its pipeline also encompasses earlier-stage cannabinoid derivatives previously explored for glaucoma and inflammatory diseases. Skye Bioscience operates in the biotechnology sector, serving patients with obesity and comorbid metabolic disorders through innovative therapies that leverage validated biologic targets for first-in-class differentiation, with global development potential from its U.S.-based operations. Founded through a 2014 reverse merger with Nemus Bioscience and renamed Skye Bioscience, Inc. in January 2021 from Emerald Bioscience, Inc., the company maintains headquarters in San Diego, California, and employs approximately 16-17 staff focused on preclinical research, clinical trials, scalable manufacturing, and strategic partnerships. Recent developments include the completion of the 26-week treatment phase in the Phase 2a CBeyond™ clinical trial of nimacimab in obesity, with topline data reported in October 2025 showing weight loss efficacy in monotherapy and combination arms, a fully enrolled 26-week extension study (topline data expected Q1 2026), and preclinical demonstrations of superior weight loss versus monlunabant alongside durable post-treatment maintenance when combined with tirzepatide; Phase 1b data presented at the European Association for the Study of Diabetes (EASD) in September 2025; a May 2025 formulation partnership with Arecor Therapeutics plc to develop a higher-concentration version of nimacimab using Arestat™ technology for improved patient convenience, with Skye funding development and retaining licensing options; and a July 2024 strategic collaboration with Beacon Biosignals to integrate AI-driven sleep monitoring into the CBeyond™ trial.
Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1
UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update
Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development
Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Recommendation of “Moderate Buy” from Analysts
Penny Stock Skye Bioscience Drug Combo With Wegovy Shows Over 22% Weight Loss After One Year
Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide
Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference
Skye Bioscience to Present Poster at Keystone Obesity Conference
Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Rating of “Moderate Buy” from Brokerages
Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE
SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm
SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience